Acadia Pharmaceuticals, Inc. (ACAD) Tops Q2 EPS by 3c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $29.27 -3.11%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) reported Q2 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $460 thousand versus the consensus estimate of $480 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Acadia Pharmaceuticals (ACAD) PT Raised to $49 at UBS
- Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
- Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
